Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XENON XE 127 vs LYMPHOSEEK KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xenon Xe 127 is a radioactive isotope that emits gamma radiation and is used as a diagnostic imaging agent. Its mechanism is based on the physical properties of radioactive decay, allowing for scintigraphic imaging of pulmonary ventilation and cerebral blood flow.
Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.
Pulmonary ventilation imaging to evaluate regional lung function,Cerebral blood flow imaging for assessment of perfusion
For lymphoscintigraphy to assist in the localization of sentinel lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.
5-10 m Ci (185-370 MBq) inhaled as a single dose for pulmonary ventilation studies.
Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.
Terminal elimination half-life is approximately 5 minutes for the washout phase from well-perfused tissues. In poorly perfused fat, a slower phase with half-life of ~30 minutes may occur. Clinically, the gas is rapidly cleared from the body upon cessation of administration.
6 hours (physical half-life of technetium-99m). Effective half-life is approximately 6 hours, allowing imaging up to 24 hours post-injection.
Not metabolized; eliminated via exhalation unchanged.
Technetium Tc-99m tilmanocept is not metabolized; it is cleared from the injection site via the lymphatic system and excreted renally.
Primarily eliminated via exhalation as unchanged gas (>95%). Minimal renal excretion of dissolved xenon (<5%). No biliary or fecal elimination due to inert nature.
Renal: 100% (as technetium-99m pertechnetate). No biliary or fecal elimination.
Negligible protein binding (<1%). Xenon is inert and does not bind significantly to plasma proteins.
Negligible (<5%), primarily to albumin.
Volume of distribution is approximately 3-5 L/kg, reflecting extensive distribution to tissues including fat, due to high lipid solubility.
Approximately 0.2 L/kg, indicating distribution within extracellular fluid.
Inhalation: Bioavailability is 100% due to direct delivery to pulmonary circulation. No other routes are clinically relevant.
Not applicable (administered parenterally).
No adjustment required as Xenon Xe 127 is eliminated via exhalation.
No dose adjustment required based on GFR, but ensure adequate hydration.
No adjustment required as Xenon Xe 127 is not hepatically metabolized.
No specific guidelines available; use with caution in severe hepatic impairment.
0.1-0.2 m Ci/kg (3.7-7.4 MBq/kg) inhaled, maximum 10 m Ci.
Not established; safety and efficacy in pediatric patients have not been studied.
No specific adjustment; use standard adult dose with caution due to potential reduced pulmonary function.
No specific dosage adjustment; monitor for adverse effects as elderly may have reduced immune response.
None.
This drug does not have a black box warning.
Radiation exposure risk; use only when necessary in pregnant women and children.,Ensure proper handling and disposal to minimize exposure to personnel and environment.
Risk of hypersensitivity reactions including anaphylaxis.,Not for intrathecal administration.,Radiation exposure risk.
Hypersensitivity to xenon or any component of the product.,Known or suspected pregnancy unless benefit outweighs risk.
Known hypersensitivity to tilmanocept or any component of the formulation.
No specific food interactions. However, patients should avoid heavy meals immediately before the study to prevent aspiration or discomfort during inhalation. No dietary restrictions otherwise.
No known food interactions. No dietary restrictions required.
Xenon Xe 127 is a radioactive gas. Exposure during pregnancy poses a risk of fetal radiation exposure. First trimester: highest risk for teratogenicity (e.g., CNS malformations, growth restriction). Second trimester: risk of growth restriction and neurodevelopmental effects. Third trimester: risk of childhood cancer and growth restriction. Consider alternative imaging modalities.
Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended doses. However, if administered intravenously, radiation exposure to the fetus could occur. No teratogenic effects are expected from the non-radioactive component (tilmanocept). Pregnancy category not assigned by FDA for diagnostic radiopharmaceuticals. Use only if clearly needed.
No data on M/P ratio. Xenon Xe 127 is rapidly excreted via lungs; minimal secretion into breast milk is expected, but due to radioactivity, breastfeeding should be interrupted for at least 48 hours post-administration.
It is unknown whether tilmanocept is excreted in human milk. Because of the low dose and local administration, systemic exposure is minimal. However, to minimize radiation exposure to the nursing infant, temporary cessation of breastfeeding for 4-6 hours after administration is recommended. M/P ratio not available.
No dosing adjustments established for pregnancy. Use lowest effective activity and minimize exposure time. Consider non-radioactive alternative due to risks.
No dose adjustment necessary. The administered activity of technetium Tc 99m tilmanocept is typically 18.5-74 MBq (0.5-2.0 m Ci) regardless of pregnancy. Pharmacokinetic changes in pregnancy are not expected to require dose modification due to local subcutaneous administration.
Xenon Xe 127 is a radioactive gas used in pulmonary ventilation studies. It is administered via inhalation. Key pearls: (1) Ensure patient does not smoke or use nicotine products for at least 6 hours prior to study to reduce background activity. (2) Scintigraphy must be performed promptly after inhalation due to short half-life (36.4 days). (3) Contamination risk is low but proper ventilation and waste disposal are critical. (4) Contraindicated in severe COPD or respiratory distress due to inability to hold breath.
Lymphoseek (technetium Tc 99m tilmanocept) is a receptor-targeted radiotracer for sentinel lymph node mapping. Administer intradermally, subcutaneously, or peritumorally. Optimal imaging time: 15-60 min post-injection. Can be used in patients with penicillin allergy as it contains no penicillin. Ensure patient is not pregnant or lactating. May cause injection site reactions.
This is a radioactive gas used to image lung ventilation.,You will inhale the gas through a mouthpiece or mask; no pain is involved.,The radiation exposure is low and similar to a chest X-ray.,Avoid smoking or using nicotine for 6 hours before the test.,Inform your doctor if you are pregnant or breastfeeding.,You may be asked to hold your breath for 10-20 seconds.,After the test, you can resume normal activities immediately.
This is a radioactive dye used to find lymph nodes during surgery.,You will receive a small injection near the tumor site.,The procedure is generally safe, but inform your doctor if you are pregnant or breastfeeding.,You may experience mild pain, redness, or swelling at the injection site.,No special dietary restrictions are needed before the procedure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XENON XE 127 vs LYMPHOSEEK KIT, answered by our medical review team.
XENON XE 127 is a Radiopharmaceutical Diagnostic Agent that works by Xenon Xe 127 is a radioactive isotope that emits gamma radiation and is used as a diagnostic imaging agent. Its mechanism is based on the physical properties of radioactive decay, allowing for scintigraphic imaging of pulmonary ventilation and cerebral blood flow.. LYMPHOSEEK KIT is a Radiopharmaceutical Diagnostic Agent that works by Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XENON XE 127 and LYMPHOSEEK KIT depend on the specific clinical indication. These are both Radiopharmaceutical Diagnostic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XENON XE 127 is: 5-10 m Ci (185-370 MBq) inhaled as a single dose for pulmonary ventilation studies.. The standard adult dose of LYMPHOSEEK KIT is: Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XENON XE 127 and LYMPHOSEEK KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XENON XE 127 is classified as Category C. Xenon Xe 127 is a radioactive gas. Exposure during pregnancy poses a risk of fetal radiation exposure. First trimester: highest risk for teratogenicity (e.g., CNS malformations, gr. LYMPHOSEEK KIT is classified as Category C. Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.